Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 1
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Angiotensin II for the Treatment of Vasodilatory Shock.
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Khanna A, et al. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21. N Engl J Med. 2017. PMID: 28528561 Free article. Clinical Trial.
The Recurrence Risk of Fetomaternal Hemorrhage.
Troìa L, Al-Kouatly HB, McCurdy R, Konchak PS, Weiner S, Berghella V. Troìa L, et al. Fetal Diagn Ther. 2019;45(1):1-12. doi: 10.1159/000491788. Epub 2018 Sep 17. Fetal Diagn Ther. 2019. PMID: 30223274 Free article.
To determine the recurrence risk of FMH after intrauterine transfusion, we performed a systematic review of all case reports/series of patients with proven FMH treated with intrauterine transfusion and who had subsequent follow-up of at least 72 h until delivery. ...Severa …
To determine the recurrence risk of FMH after intrauterine transfusion, we performed a systematic review of all case reports/series of patie …
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.
Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M. Bashey A, et al. J Clin Oncol. 2017 Sep 10;35(26):3002-3009. doi: 10.1200/JCO.2017.72.8428. Epub 2017 Jun 23. J Clin Oncol. 2017. PMID: 28644773 Free PMC article. Clinical Trial.
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, Graham TB, Ibarra M, Ilowite N, Klein-Gitelman M, Onel K, Prahalad S, Punaro M, Ringold S, Toib D, Van Mater H, Weiss JE, Weiss PF, Schanberg LE; CARRA Registry Investigators. Kimura Y, et al. Pediatr Rheumatol Online J. 2017 Apr 11;15(1):23. doi: 10.1186/s12969-017-0157-1. Pediatr Rheumatol Online J. 2017. PMID: 28399931 Free PMC article. Clinical Trial.
Intraoperative fetal heart monitoring for non-obstetric surgery: A systematic review.
Po' G, Olivieri C, Rose CH, Saccone G, McCurdy R, Berghella V. Po' G, et al. Eur J Obstet Gynecol Reprod Biol. 2019 Jul;238:12-19. doi: 10.1016/j.ejogrb.2019.04.033. Epub 2019 Apr 27. Eur J Obstet Gynecol Reprod Biol. 2019. PMID: 31082738
Two (4.9%) cases of non-reassuring fetal heart rate monitoring were noted within the immediate 48 h after surgery, necessitating cesarean delivery. ...Fetal heart rate monitoring during non-obstetric surgery at ≥22 weeks was not associated with need for intraoperative cesa …
Two (4.9%) cases of non-reassuring fetal heart rate monitoring were noted within the immediate 48 h after surgery, necessitating cesa …
Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial.
Ham KR, Boldt DW, McCurdy MT, Busse LW, Favory R, Gong MN, Khanna AK, Chock SN, Zeng F, Chawla LS, Tidmarsh GF, Ostermann M. Ham KR, et al. Ann Intensive Care. 2019 Jun 3;9(1):63. doi: 10.1186/s13613-019-0536-5. Ann Intensive Care. 2019. PMID: 31161442 Free PMC article.
Patients in the ≤ 5 ng kg(-1) min(-1) subgroup were more likely to have a MAP response at 3 h versus those in the > 5 ng kg(-1) min(-1) subgroup (90% vs. 51%, respectively; odds ratio, 8.46 [95% CI 3.63-19.7], P < 0.001). ...
Patients in the ≤ 5 ng kg(-1) min(-1) subgroup were more likely to have a MAP response at 3 h versus those in the > 5 ng kg(-1) mi …
Feedback